

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/825,084	04/15/2004	Jeffery R. Raymond	480117.412	7178	
500 SEED INTEL I	500 7590 12/20/2007 SEED INTELLECTUAL PROPERTY LAW GROUP PLLC			EXAMINER	
701 FIFTH AVE			BADIO, BARBARA P		
SUITE 5400	SUITE 5400 SEATTLE, WA 98104		ART UNIT	PAPER NUMBER	
SEATTEE, WAY 70104			1617		
			MAIL DATE	DELIVERY MODE	
		•	12/20/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/825,084	RAYMOND ET AL.				
Office Action Summary	Examiner	Art Unit				
	Barbara P. Badio, Ph.D.	1617				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	I. hely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on						
,	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.  Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) 1-29 is/are pending in the application. 4a) Of the above claim(s) 5,6,9-21 and 24-29 is 5) Claim(s) is/are allowed. 6) Claim(s) 1-4,7,22 and 23 is/are rejected.		on.				
7)⊠ Claim(s) <u>8</u> is/are objected to. 8)□ Claim(s) are subject to restriction and/o	r election requirement.					
Application Papers	•					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicated any not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	epted or b) objected to by the l drawing(s) be held in abeyance. Section is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119	·					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document: 2. Certified copies of the priority document: 3 Copies of the certified copies of the priority document: application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date 7/5/07;3/31/05,8/27/04	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate				

10/825,084 Art Unit: 1617

### First Office Action on the Merits

#### Election/Restrictions

- 1. Applicant's election without traverse of Group I and the compound #78 found in the present specification in the reply filed on October 11, 2007 is acknowledged.
- 2. Based on applicant's elected species, claims 5, 6, 9-21 and 24-29 stand withdrawn from further consideration as being drawn to a nonelected invention. Claims 1-4, 7, 8, 22 and 23 will be examined to the extent they read on the elected species and obvious variants thereof.

## Claim Rejections - 35 USC § 112

- 3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

  The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 4. Claims 1 and 22 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The instant claims recite "or a pharmaceutically acceptable salt, solvate or prodrug thereof, <u>in isolation or in a mixture</u>". It is noted that the claims include single stereoisomers and mixtures of said isomers and, thus, it is unclear what is intended by "in isolation or in a mixture".

10/825,084 Art Unit: 1617

### Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

6. Claims 1-4, 7, 22 and 23 are rejected under 35 U.S.C. 102(b) as being anticipated by Lettre et al. (DE 1,084,718).

Letter et al. teaches secosteroids such as 6-amino-5,6-secocholestane-3β,5-diol and 6-dimethylamino-5,6-secocholestane-3β,5β-diol (see cols. 3-4, Examples 1-4; see also attached English abstract, RNs 103099-54-3 and 105520-54-5). The reference teaches the compounds are useful pharmaceuticals (see attached English abstract). The compounds and compositions taught by the reference are encompassed by the instant claims.

7. Claims 1-4, 22 and 23 are rejected under 35 U.S.C. 102(b) as being anticipated by Oshida (JP 1,290,624).

Oshida teaches the 5,6-secosteroids such as 5,6-secocholestane-1,3,6-triol as anticholesteremics and hypolipemics (see the English Abstract, RN 126922-88-1). The compounds and compositions taught by the reference are encompassed by the instant claims.

Application/Control Number:

10/825,084 Art Unit: 1617

# Claim Objections

Claim 8 is objected to as being dependent upon a rejected base claim. 8. Note: The instant claim would be allowable to the extent it reads on the elected species.

# Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the 9. examiner should be directed to Barbara P. Badio, Ph.D. whose telephone number is 571-272-0609. The examiner can normally be reached on M-F from 6:30am-4:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Barbara P. Badiø, Ph.D.

Primary Examiner

Art Unit 1617